PT3470077T - Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas - Google Patents
Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonasInfo
- Publication number
- PT3470077T PT3470077T PT182019604T PT18201960T PT3470077T PT 3470077 T PT3470077 T PT 3470077T PT 182019604 T PT182019604 T PT 182019604T PT 18201960 T PT18201960 T PT 18201960T PT 3470077 T PT3470077 T PT 3470077T
- Authority
- PT
- Portugal
- Prior art keywords
- diseases
- pharmacological chaperone
- predict response
- chaperone treatment
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2814108P | 2008-02-12 | 2008-02-12 | |
| US3568408P | 2008-03-11 | 2008-03-11 | |
| US9363108P | 2008-09-02 | 2008-09-02 | |
| US11349608P | 2008-11-11 | 2008-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3470077T true PT3470077T (pt) | 2020-11-30 |
Family
ID=40957500
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97101786T PT2252313E (pt) | 2008-02-12 | 2009-02-12 | Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas |
| PT15162630T PT2946785T (pt) | 2008-02-12 | 2009-02-12 | Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas |
| PT182019604T PT3470077T (pt) | 2008-02-12 | 2009-02-12 | Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97101786T PT2252313E (pt) | 2008-02-12 | 2009-02-12 | Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas |
| PT15162630T PT2946785T (pt) | 2008-02-12 | 2009-02-12 | Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US8592362B2 (pt) |
| EP (4) | EP2252313B1 (pt) |
| JP (6) | JP5844045B2 (pt) |
| AU (6) | AU2009214648B2 (pt) |
| CA (1) | CA2715407C (pt) |
| CY (3) | CY1116466T1 (pt) |
| DK (3) | DK2252313T3 (pt) |
| ES (3) | ES2716502T3 (pt) |
| HR (3) | HRP20150728T1 (pt) |
| HU (3) | HUE042882T2 (pt) |
| LT (2) | LT3470077T (pt) |
| MX (1) | MX2010008835A (pt) |
| PL (3) | PL2252313T3 (pt) |
| PT (3) | PT2252313E (pt) |
| SI (3) | SI2252313T1 (pt) |
| WO (1) | WO2009102895A2 (pt) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2709445T3 (es) | 2006-05-16 | 2019-04-16 | Amicus Therapeutics Inc | Opciones de tratamiento para la enfermedad de Fabry |
| DK2252313T3 (en) | 2008-02-12 | 2015-07-13 | Amicus Therapeutics Inc | METHOD TO PREDICT response to Pharmacological chaperone TREATMENT OF DISEASES |
| US20110136151A1 (en) * | 2008-03-12 | 2011-06-09 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for pompe disease |
| TW201117810A (en) * | 2009-10-01 | 2011-06-01 | Baylor Res Inst | Treatment of male-pattern baldness by local induction of the metabolic defect of fabry disease |
| US20120283290A1 (en) * | 2011-05-06 | 2012-11-08 | Amicus Therapeutics Inc. | Quantitation of gl3 in urine |
| PL3201320T3 (pl) | 2014-09-30 | 2024-03-18 | Amicus Therapeutics, Inc. | Bardzo silnie działająca kwasowa alfa-glukozydaza ze zwiększoną zawartością węglowodanów |
| AU2016233135B2 (en) | 2015-03-19 | 2021-07-08 | Translate Bio, Inc. | mRNA therapy for pompe disease |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| BR112018013151A2 (pt) | 2015-12-30 | 2018-12-18 | Amicus Therapeutics Inc | alfa-glicosidase ácida aumentada para o tratamento da doença de pompe |
| SI3957320T1 (sl) | 2015-12-30 | 2024-01-31 | Amicus Therapeutics, Inc., | Dopolnjena kisla alfa glukozidaza za zdravljenje Pompejeve bolezni |
| EP3432882B1 (en) * | 2016-03-22 | 2021-09-01 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having the g9331a mutation in the gla gene |
| WO2017173059A1 (en) * | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| WO2017173060A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
| TWI813388B (zh) | 2016-03-30 | 2023-08-21 | 美商阿米庫斯醫療股份有限公司 | 包含重組酸性α-葡萄糖苷酶之調配物 |
| US20190183869A1 (en) | 2016-07-19 | 2019-06-20 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| JP6546135B2 (ja) | 2016-08-24 | 2019-07-17 | 株式会社ノリタケカンパニーリミテド | 積層造形焼成体、積層造形焼成体の製造方法および積層造形焼成体製造用キット |
| EP3528852A4 (en) * | 2016-10-20 | 2020-06-03 | Sangamo Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY'S DISEASE |
| EA039750B1 (ru) * | 2017-03-30 | 2022-03-10 | Амикус Терапьютикс, Инк. | Способ отбора рекомбинантных белков с высоким содержанием m6p |
| AU2018270925A1 (en) | 2017-05-15 | 2019-11-28 | Amicus Therapeutics, Inc. | Recombinant human acid alpha-glucosidase |
| CA3065298A1 (en) | 2017-05-30 | 2018-12-06 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| CN111278438A (zh) | 2017-05-30 | 2020-06-12 | 阿米库斯治疗学公司 | 治疗具有肾损害的法布里患者的方法 |
| SG11202000423XA (en) | 2017-07-19 | 2020-02-27 | Amicus Therapeutics Inc | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| HRP20221366T1 (hr) | 2017-08-28 | 2023-01-06 | Amicus Therapeutics, Inc. | Postupci poboljšanja i/ili stabilizacije srčane funkcije kod bolesnika s fabrijevom bolešću |
| WO2019157047A1 (en) | 2018-02-06 | 2019-08-15 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| DK3749308T3 (da) | 2018-02-06 | 2024-01-22 | Amicus Therapeutics Inc | Behandling af patienter med klassisk fabrys sygdom med migalastat |
| WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| BR112021003137A2 (pt) | 2018-08-20 | 2021-05-11 | Amicus Therapeutics, Inc. | métodos de tratamento de doença de fabry em pacientes com uma mutação no gene gla |
| WO2020046132A1 (en) | 2018-08-31 | 2020-03-05 | Leiden University | Pharmacological chaperones for enzyme treatment therapy |
| NL2021840B1 (en) | 2018-10-19 | 2020-05-13 | Univ Leiden | Pharmacological Chaperones For Enzyme Treatment Therapy |
| TW202042812A (zh) | 2019-01-22 | 2020-12-01 | 美商阿米庫斯醫療股份有限公司 | 減少法布瑞氏症患者中之腦血管事件之方法 |
| JP2022536687A (ja) | 2019-06-11 | 2022-08-18 | アミカス セラピューティックス インコーポレイテッド | 腎機能障害を有する患者のファブリー病を治療する方法 |
| TW202120087A (zh) * | 2019-08-07 | 2021-06-01 | 美商阿米庫斯醫療股份有限公司 | 治療在GLA基因中具有突變的患者的Fabry氏病之方法 |
| EP4025242A1 (en) | 2019-09-06 | 2022-07-13 | Amicus Therapeutics, Inc. | Method for capturing and purification of biologics |
| JP2023516753A (ja) * | 2020-03-06 | 2023-04-20 | アミカス セラピューティックス インコーポレイテッド | Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法 |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| CA3225511A1 (en) | 2021-07-12 | 2023-01-19 | Franklin Johnson | Methods of treating fabry disease in pediatric patients |
| WO2023215865A1 (en) | 2022-05-05 | 2023-11-09 | Amicus Therapeutics, Inc. | Methods for treating pompe disease |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3586908A (en) | 1969-02-28 | 1971-06-22 | Robert E Vosteen | Automatic potential control system for electrophotography apparatus |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| US5844102A (en) | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
| WO1997037645A1 (en) | 1996-04-10 | 1997-10-16 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
| US6270954B1 (en) | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
| US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US6244113B1 (en) | 1999-10-29 | 2001-06-12 | University Of Alabama In Huntsville | Method and apparatus for measuring microgravity acceleration |
| US7842470B2 (en) * | 2001-10-09 | 2010-11-30 | Oregon Health & Science University | Method for pharmacoperones correction of GnRHR mutant protein misfolding |
| EP3441090A1 (en) * | 2005-05-17 | 2019-02-13 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| CA2611011C (en) * | 2005-06-08 | 2014-01-28 | Amicus Therapeutics, Inc. | Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes |
| JP5107350B2 (ja) | 2005-06-08 | 2012-12-26 | アミカス セラピューティックス インコーポレイテッド | イミノおよびアミノ糖の精製 |
| WO2007089591A2 (en) * | 2006-01-27 | 2007-08-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for high throughput screening of pharmacological chaperones |
| ES2709445T3 (es) | 2006-05-16 | 2019-04-16 | Amicus Therapeutics Inc | Opciones de tratamiento para la enfermedad de Fabry |
| WO2007140212A2 (en) | 2006-05-24 | 2007-12-06 | Amicus Therapeutics, Inc. | Tartrate salt of isofagomine and methods of use |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2150254A4 (en) | 2007-04-26 | 2010-11-10 | Amicus Therapeutics Inc | DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES |
| US20110152319A1 (en) | 2008-02-12 | 2011-06-23 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| DK2252313T3 (en) | 2008-02-12 | 2015-07-13 | Amicus Therapeutics Inc | METHOD TO PREDICT response to Pharmacological chaperone TREATMENT OF DISEASES |
| US8321148B2 (en) | 2008-10-24 | 2012-11-27 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
| JP5805630B2 (ja) | 2009-05-26 | 2015-11-04 | アミカス セラピューティックス インコーポレイテッド | 生物製剤の製造および精製を改善するための薬理学的シャペロンの利用 |
| US9206457B2 (en) | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| CA2781277C (en) | 2009-11-17 | 2018-01-09 | Baylor Research Institute | Urinary triaosylceramide (gb3) as a marker of cardiac disease |
| SG10201604757RA (en) | 2011-03-11 | 2016-08-30 | Amicus Therapeutics Inc | Dosing regimens for the treatment of fabry disease |
| EP2874648A4 (en) | 2012-07-17 | 2015-12-30 | Amicus Therapeutics Inc | CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN |
| US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
| EP3432882B1 (en) | 2016-03-22 | 2021-09-01 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having the g9331a mutation in the gla gene |
| US20190183869A1 (en) | 2016-07-19 | 2019-06-20 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| JP2020503900A (ja) | 2017-01-10 | 2020-02-06 | アミカス セラピューティックス インコーポレイテッド | ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ |
| CA3065298A1 (en) | 2017-05-30 | 2018-12-06 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| SG11202000423XA (en) | 2017-07-19 | 2020-02-27 | Amicus Therapeutics Inc | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| HRP20221366T1 (hr) | 2017-08-28 | 2023-01-06 | Amicus Therapeutics, Inc. | Postupci poboljšanja i/ili stabilizacije srčane funkcije kod bolesnika s fabrijevom bolešću |
| DK3749308T3 (da) | 2018-02-06 | 2024-01-22 | Amicus Therapeutics Inc | Behandling af patienter med klassisk fabrys sygdom med migalastat |
| WO2019157047A1 (en) | 2018-02-06 | 2019-08-15 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| BR112021003137A2 (pt) | 2018-08-20 | 2021-05-11 | Amicus Therapeutics, Inc. | métodos de tratamento de doença de fabry em pacientes com uma mutação no gene gla |
| JP2022536687A (ja) | 2019-06-11 | 2022-08-18 | アミカス セラピューティックス インコーポレイテッド | 腎機能障害を有する患者のファブリー病を治療する方法 |
| TW202120087A (zh) | 2019-08-07 | 2021-06-01 | 美商阿米庫斯醫療股份有限公司 | 治療在GLA基因中具有突變的患者的Fabry氏病之方法 |
-
2009
- 2009-02-12 DK DK09710178.6T patent/DK2252313T3/en active
- 2009-02-12 DK DK18201960.4T patent/DK3470077T3/da active
- 2009-02-12 DK DK15162630.6T patent/DK2946785T3/en active
- 2009-02-12 EP EP09710178.6A patent/EP2252313B1/en active Active
- 2009-02-12 ES ES15162630T patent/ES2716502T3/es active Active
- 2009-02-12 PT PT97101786T patent/PT2252313E/pt unknown
- 2009-02-12 PT PT15162630T patent/PT2946785T/pt unknown
- 2009-02-12 LT LTEP18201960.4T patent/LT3470077T/lt unknown
- 2009-02-12 EP EP15162630.6A patent/EP2946785B1/en active Active
- 2009-02-12 PL PL09710178T patent/PL2252313T3/pl unknown
- 2009-02-12 SI SI200931229T patent/SI2252313T1/sl unknown
- 2009-02-12 ES ES18201960T patent/ES2836121T3/es active Active
- 2009-02-12 PL PL15162630T patent/PL2946785T3/pl unknown
- 2009-02-12 WO PCT/US2009/033963 patent/WO2009102895A2/en active Application Filing
- 2009-02-12 SI SI200932099T patent/SI3470077T1/sl unknown
- 2009-02-12 EP EP20192637.5A patent/EP3824900A1/en active Pending
- 2009-02-12 CA CA2715407A patent/CA2715407C/en active Active
- 2009-02-12 AU AU2009214648A patent/AU2009214648B2/en active Active
- 2009-02-12 HU HUE15162630A patent/HUE042882T2/hu unknown
- 2009-02-12 JP JP2010546901A patent/JP5844045B2/ja active Active
- 2009-02-12 LT LTEP15162630.6T patent/LT2946785T/lt unknown
- 2009-02-12 PT PT182019604T patent/PT3470077T/pt unknown
- 2009-02-12 ES ES09710178.6T patent/ES2541933T3/es active Active
- 2009-02-12 EP EP18201960.4A patent/EP3470077B1/en active Active
- 2009-02-12 SI SI200931920T patent/SI2946785T1/sl unknown
- 2009-02-12 MX MX2010008835A patent/MX2010008835A/es active IP Right Grant
- 2009-02-12 PL PL18201960T patent/PL3470077T3/pl unknown
- 2009-02-12 HU HUE18201960A patent/HUE051377T2/hu unknown
- 2009-02-12 HU HUE09710178A patent/HUE026543T2/hu unknown
-
2010
- 2010-08-12 US US12/855,468 patent/US8592362B2/en not_active Ceased
-
2013
- 2013-10-15 US US14/054,369 patent/US9095584B2/en active Active
-
2014
- 2014-09-10 AU AU2014221321A patent/AU2014221321B2/en active Active
- 2014-12-02 JP JP2014244283A patent/JP2015091239A/ja active Pending
-
2015
- 2015-06-05 US US14/731,603 patent/US9545397B2/en active Active
- 2015-07-06 HR HRP20150728TT patent/HRP20150728T1/hr unknown
- 2015-07-08 CY CY20151100595T patent/CY1116466T1/el unknown
-
2016
- 2016-03-01 JP JP2016039171A patent/JP6672013B2/ja active Active
- 2016-07-20 AU AU2016206297A patent/AU2016206297A1/en not_active Abandoned
- 2016-09-19 US US15/268,662 patent/US20170003301A1/en not_active Abandoned
-
2017
- 2017-11-30 AU AU2017268649A patent/AU2017268649A1/en not_active Abandoned
-
2018
- 2018-07-26 US US16/046,247 patent/US10813921B2/en active Active
- 2018-12-17 US US16/222,305 patent/USRE48608E1/en active Active
- 2018-12-27 JP JP2018245609A patent/JP6837469B2/ja active Active
-
2019
- 2019-01-22 HR HRP20190143TT patent/HRP20190143T1/hr unknown
- 2019-01-24 CY CY20191100100T patent/CY1121386T1/el unknown
- 2019-08-20 AU AU2019219727A patent/AU2019219727B2/en active Active
-
2020
- 2020-10-26 US US17/079,859 patent/US20210251971A1/en active Pending
- 2020-11-17 HR HRP20201827TT patent/HRP20201827T1/hr unknown
- 2020-11-25 CY CY20201101114T patent/CY1123816T1/el unknown
-
2021
- 2021-02-09 JP JP2021019383A patent/JP7277493B2/ja active Active
- 2021-08-20 AU AU2021218172A patent/AU2021218172A1/en active Pending
-
2023
- 2023-05-08 JP JP2023076515A patent/JP2023109807A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190143T1 (hr) | Postupak za predviđanje odgovora na liječenje bolesti farmakološkim šaperonom | |
| HK1217763A1 (zh) | 用於治療疾病的方法 | |
| HK1176870A1 (zh) | 疾病的治療方法 | |
| EP2416803A4 (en) | NEW METHODS OF TREATING INFLAMMATORY DISEASES | |
| PL2504698T3 (pl) | Sposób przewidywania odpowiedzi choroby nowotworowej na środek terapeutyczny |